AptaBio Therapeutics Inc. (293780.KQ)
KRW 7290.0
(1.25%)
KRW 7290.0
(1.25%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 92.51 Billion KRW | 64.88% |
| 2022 | 56.11 Billion KRW | -13.55% |
| 2021 | 64.91 Billion KRW | -13.96% |
| 2020 | 75.44 Billion KRW | -2.53% |
| 2019 | 77.4 Billion KRW | 280.77% |
| 2018 | 20.32 Billion KRW | 90.56% |
| 2017 | 10.66 Billion KRW | -15.37% |
| 2016 | 12.6 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 88.75 Billion KRW | -1.25% |
| 2024 Q1 | 89.88 Billion KRW | -2.85% |
| 2023 Q3 | 100.94 Billion KRW | 101.69% |
| 2023 FY | 92.51 Billion KRW | 64.88% |
| 2023 Q4 | 92.51 Billion KRW | -8.35% |
| 2023 Q2 | 50.05 Billion KRW | -3.69% |
| 2023 Q1 | 51.97 Billion KRW | -7.38% |
| 2022 Q2 | 60.77 Billion KRW | -3.42% |
| 2022 Q1 | 62.92 Billion KRW | -3.06% |
| 2022 Q4 | 56.11 Billion KRW | -3.7% |
| 2022 Q3 | 58.27 Billion KRW | -4.11% |
| 2022 FY | 56.11 Billion KRW | -13.55% |
| 2021 Q1 | 72.68 Billion KRW | -3.66% |
| 2021 FY | 64.91 Billion KRW | -13.96% |
| 2021 Q4 | 64.91 Billion KRW | -2.84% |
| 2021 Q3 | 66.81 Billion KRW | -5.24% |
| 2021 Q2 | 70.5 Billion KRW | -2.99% |
| 2020 Q2 | 77.28 Billion KRW | -0.88% |
| 2020 FY | 75.44 Billion KRW | -2.53% |
| 2020 Q4 | 75.44 Billion KRW | -2.36% |
| 2020 Q3 | 77.26 Billion KRW | -0.02% |
| 2020 Q1 | 77.97 Billion KRW | 0.73% |
| 2019 Q2 | 81.12 Billion KRW | 0.0% |
| 2019 Q4 | 77.4 Billion KRW | -3.73% |
| 2019 Q3 | 80.4 Billion KRW | -0.89% |
| 2019 FY | 77.4 Billion KRW | 280.77% |
| 2018 Q4 | 20.32 Billion KRW | 0.0% |
| 2018 FY | 20.32 Billion KRW | 90.56% |
| 2017 FY | 10.66 Billion KRW | -15.37% |
| 2016 FY | 12.6 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 141.35 Billion KRW | 34.547% |
| CMG Pharmaceutical Co., Ltd. | 186.85 Billion KRW | 50.485% |
| Celltrion Pharm, Inc. | 641.64 Billion KRW | 85.581% |
| Huons Global Co., Ltd. | 1317.96 Billion KRW | 92.98% |
| DongKook Pharmaceutical Co., Ltd. | 839.53 Billion KRW | 88.98% |
| Enzychem Lifesciences Corporation | 211.54 Billion KRW | 56.265% |
| Humedix Co., Ltd. | 219.97 Billion KRW | 57.942% |
| Boditech Med Inc. | 227.9 Billion KRW | 59.404% |
| EuBiologics Co., Ltd. | 172.64 Billion KRW | 46.41% |
| FutureChem Co.,Ltd | 72.83 Billion KRW | -27.029% |
| Huons Co., Ltd. | 537.28 Billion KRW | 82.78% |
| BNC Korea Co., Ltd. | 236.15 Billion KRW | 60.822% |